Nanotechnology CDMO in Europe for sale

Company for sale

• Sales: < 10 million EUR
• Location: Europe
• Reason for sale: The owners are looking for a strategic partner to help the company expand
• #CFIE PHS177

Overview of nanotechnology CDMO in Europe for sale

Essentially, the company is a startup with modern technology. In particular, it uses cutting-edge supercritical CO2 technology and microfluidics to extract value-added products and produce nanoparticles.

Currently, the company wants to partner with a strategic acquirer who can drive accelerated access to a global customer base.

Profile (strategy) of nanotechnology CDMO in Europe for sale

Overall, the company has state-of-the-art equipment for a supercritical technology scale-up. Altogether, this covers the full train from laboratory-scale research to full industrial production. In addition, it also owns all the necessary analytical equipment required to characterize products and monitor processes in a GMP-certified facility.

Notably, the company offers an outstanding all-in-one model. More specifically, research, analytical, process development, and commercial scale infrastructure for cutting-edge processes. In total, the company has three units. A GMP-certified R&D unit, a supercritical fluid extraction (SCFE) unit, and a nanoparticle production unit. Currently, there is an existing R&D center and they are building new SCFE and nanoparticle production units. In January 2024 and December 2024, respectively, these units will be commissioned.

Most significantly, the research center is equipped with state-of-the-art analytical instruments. Thus, offering a full range of spectroscopy, chromatography, thermogravimetry, particle counter, and other instruments.

• R&D unit: This unit is already functional and serves as the hub for innovative processes in supercritical fluid extraction and microfluidics for nanoparticle formulation.
• SCFE production unit: Focused on supercritical fluid extraction (SCFE) processes. This unit is in a new, dedicated industrial building and is responsible for pilot and commercial-scale production. Commissioning is due in January 2024.
• Nanoparticle production unit: Utilizes supercritical microfluidic technologies for nanoparticle production. This unit will be housed in a new building adjacent to the SCFE production unit to be commissioned at the end of 2024.

Activities and products of nanotechnology CDMO in Europe for sale

Chiefly, the company uses cutting-edge supercritical fluid technology for solventless extrac5on and microfluidic encapsulation and pulverization. Moreover, they are equipped with full train R&D and commercial production capabilities.

Supercritical microfluidics are used in preparing nanoparticles for a range of applications from bioactive encapsulation such as LNP for mRNA to metal-organic frameworks for green energy storage.

Highlights of nanotechnology CDMO in Europe for sale

• GMP-certified facility
• State-of-the-art equipment covering the full train for supercritical technology scale-up from laboratory scale research to full industrial production
• R&D and production facilities are already aligned with the EU legal requirements and regulations
• Cutting-edge supercritical CO2 technology and microfluidics to extract value-added products and produce nanoparticles

More information on this nanotechnology CDMO in Europe for sale

Please get in touch if you are interested in learning more about this nanotechnology CDMO in Europe for sale. For more pharma manufacturer companies for sale please visit the section pharma manufacturer companies for sale. For other pharma manufacturer buyers, please visit the section pharma manufacturer companies wanted. If you are instead interested in companies for sale, please visit the companies for sale section. For buyers, please visit the section companies wanted.